FDA Approved: ORIAHNN — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for ORIAHNN, a fixed-dose combination of elagolix, estradiol, and norethindrone by AbbVie. The approval relates to its i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heavy Menstrual Bleeding
• Uterine Fibroids

Drugs mentioned

• ORIAHNN (ELAGOLIX AND ESTRADIOL AND NORETHISTERONE)

Snippet

SUPPL AP for ORIAHNN (ELAGOLIX AND ESTRADIOL AND NORETHISTERONE)